Were the United Therapeutics (UTHR) CFO’s June 2026 share sales under a Rule 10b5-1 plan?

Yes. The filing states the stock option exercise and subsequent share sales were executed pursuant to a Rule 10b5‑1 trading plan. That plan was entered into by CFO James Edgemond on October 31, 2025, indicating the transactions were pre‑scheduled rather than newly arranged.

United Therapeutics (UTHR) CFO exercises options and sells 10K shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

United Therapeutics Corp CFO and Treasurer James Edgemond reported an options exercise and related share sales in company common stock. On June 8, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share to acquire 10,000 shares.

That same day, he sold 10,000 common shares in a series of open‑market transactions at weighted average prices ranging from the mid‑$540s to low‑$550s per share. According to the filing, these trades were made under a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025.

Following these transactions, Edgemond directly holds 18,876 shares of United Therapeutics common stock, and the filing shows no remaining derivative (stock option) position tied to this grant.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($5,475,045)

Net Sell 10 txns

Insider EDGEMOND JAMES

Role CFO AND TREASURER

Sold 10,000 shs ($5.48M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	10,000	$0.00	--
Exercise	Common Stock	10,000	$117.76	$1.18M
Sale	Common Stock	1,565	$544.9334	$853K
Sale	Common Stock	1,989	$546.1339	$1.09M
Sale	Common Stock	1,888	$547.0292	$1.03M
Sale	Common Stock	2,158	$547.9111	$1.18M
Sale	Common Stock	425	$549.3819	$233K
Sale	Common Stock	1,285	$550.0937	$707K
Sale	Common Stock	610	$551.2826	$336K
Sale	Common Stock	80	$551.755	$44K

Holdings After Transaction: Stock Option — 20,000 shares (Direct, null); Common Stock — 28,876 shares (Direct, null)

Footnotes (1)

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $544.41 to $545.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $545.47 to $546.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $546.51 to $547.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $547.52 to $548.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $548.59 to $549.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $549.59 to $550.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $550.63 to $551.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $551.74 to $551.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Common shares sold: 10,000 shares Sale price range: $544.41–$551.77 per share Options exercised: 10,000 options +3 more

6 metrics

Common shares sold 10,000 shares Open-market sales of United Therapeutics common stock on June 8, 2026

Sale price range $544.41–$551.77 per share Weighted average prices across multiple trades on June 8, 2026

Options exercised 10,000 options Stock options converted into common shares on June 8, 2026

Option exercise price $117.76 per share Exercise price for 10,000 stock options

Shares held after transactions 18,876 shares Direct common stock ownership after June 8, 2026 trades

Option expiration date March 15, 2027 Original expiration date of the exercised stock options

Key Terms

Rule 10b5-1 trading plan, stock options, weighted average price, derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock options financial

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open market or private transaction financial

"Sale in open market or private transaction"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 06:51 PM Accepted by SEC EDGAR 06/09/2026 - 06:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO AND TREASURER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		M⁽¹⁾		10,000	A	$117.76	28,876	D
Common Stock	06/08/2026		S⁽¹⁾		1,565	D	$544.9334⁽²⁾	27,311	D
Common Stock	06/08/2026		S⁽¹⁾		1,989	D	$546.1339⁽³⁾	25,322	D
Common Stock	06/08/2026		S⁽¹⁾		1,888	D	$547.0292⁽⁴⁾	23,434	D
Common Stock	06/08/2026		S⁽¹⁾		2,158	D	$547.9111⁽⁵⁾	21,276	D
Common Stock	06/08/2026		S⁽¹⁾		425	D	$549.3819⁽⁶⁾	20,851	D
Common Stock	06/08/2026		S⁽¹⁾		1,285	D	$550.0937⁽⁷⁾	19,566	D
Common Stock	06/08/2026		S⁽¹⁾		610	D	$551.2826⁽⁸⁾	18,956	D
Common Stock	06/08/2026		S⁽¹⁾		80	D	$551.755⁽⁹⁾	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$117.76	06/08/2026		M⁽¹⁾			10,000	03/15/2023	03/15/2027	Common Stock	10,000	$0.00	20,000	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $544.41 to $545.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $545.47 to $546.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $546.51 to $547.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $547.52 to $548.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $548.59 to $549.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $549.59 to $550.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $550.63 to $551.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $551.74 to $551.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did United Therapeutics (UTHR) report for CFO James Edgemond?

United Therapeutics reported that CFO James Edgemond exercised 10,000 stock options and sold 10,000 common shares on June 8, 2026. The sales were executed in multiple open‑market trades at weighted average prices in the mid‑$540s to low‑$550s per share.

How many United Therapeutics (UTHR) shares does the CFO hold after the Form 4 transactions?

After the reported transactions, CFO James Edgemond directly holds 18,876 shares of United Therapeutics common stock. This figure reflects his position following the June 8, 2026 option exercise of 10,000 shares and related open‑market sales totaling 10,000 shares.

What was the exercise price of the United Therapeutics (UTHR) stock options used by the CFO?

The Form 4 shows that 10,000 stock options were exercised at an exercise price of $117.76 per share. These options, granted earlier, were converted into 10,000 shares of United Therapeutics common stock before the same‑day open‑market sales.

At what prices did the United Therapeutics (UTHR) CFO sell his common shares?

The reported sales occurred in multiple trades at weighted average prices generally between about $544 and $552 per share. Individual transactions were executed in price ranges such as $544.41–$545.40 and $550.63–$551.60, according to the detailed price ranges in the footnotes.

What happened to the CFO’s United Therapeutics stock options in this Form 4 filing?

The filing shows 10,000 stock options were exercised into 10,000 common shares on June 8, 2026, at a $117.76 exercise price. The derivative summary is empty afterward, indicating this specific option position was fully exercised with no remaining derivative shares from that grant.